Related Experiment Video
Updated: Jun 16, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
Alternative splicing regulates FGGY-derived neoantigen presentation and promotes immune evasion in
Li Na Zhao1, Jesper B Andersen1
1Department of Health and Medical Sciences, Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
The elucidation of actionable, tumor-specific neoantigens remains a challenge in cancer immunotherapy. We identify FGGY-204, an alternatively spliced isoform of FGGY, as a source of tumor-specific neoantigen presentation. FGGY-204 expression is elevated in HCC and encodes a cryptic peptide that is derived from the primate-specific exon 12. This neoantigen candidate peptide is repressed in the normal liver parenchyma by a multifaceted regulatory program, where the FGGY exon 12 locus is epigenetically silenced by abrogated active chromatin marks and DNA methylation. Exon 12 inclusion is directly suppressed by HNRNPA1, whose silencing promotes FGGY-204 biogenesis, revealing a repressive mechanism with potential in therapy. Critically, FGGY-204 expression defines immune-cold HCC tumors, inversely correlated with CD8+ T cell tumor infiltration and antigen presentation. Its immune association dynamically shifts in response to immunotherapy. FGGY-204 presents a neopeptide, a potential immunotherapeutic target, revealing its precise molecular mechanism of control as an entry point to modulate tumor immunogenicity.
The elucidation of actionable, tumor-specific neoantigens remains a challenge in cancer immunotherapy. We identify FGGY-204, an alternatively spliced isoform of FGGY, as a source of tumor-specific neoantigen presentation. FGGY-204 expression is elevated in HCC and encodes a cryptic peptide that is derived from the primate-specific exon 12. This neoantigen candidate peptide is repressed in the normal liver parenchyma by a multifaceted regulatory program, where the FGGY exon 12 locus is epigenetically silenced by abrogated active chromatin marks and DNA methylation. Exon 12 inclusion is directly suppressed by HNRNPA1, whose silencing promotes FGGY-204 biogenesis, revealing a repressive mechanism with potential in therapy. Critically, FGGY-204 expression defines immune-cold HCC tumors, inversely correlated with CD8+ T cell tumor infiltration and antigen presentation. Its immune association dynamically shifts in response to immunotherapy. FGGY-204 presents a neopeptide, a potential immunotherapeutic target, revealing its precise molecular mechanism of control as an entry point to modulate tumor immunogenicity.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

